Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The Effect of Ivermectin on Reducing Viral Symptoms in Patients with Mild COVID-19

Abbas et al., Indian Journal of Pharmaceutical Sciences, doi:10.36468/pharmaceutical-sciences.spl.416
Dec 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -4% Improvement Relative Risk Deterioration of 2 or more.. 41% Escalation of care 15% Fever during study 18% Recovery 36% primary Recovery time 31% primary Ivermectin  Abbas et al.  EARLY TREATMENT  DB RCT Is early treatment with ivermectin beneficial for COVID-19? Double-blind RCT 202 patients in China (May - August 2021) Improved recovery with ivermectin (p=0.037) Abbas et al., Indian J. Pharmaceutical.., Dec 2021 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments.
RCT 99 ivermectin and 103 control low risk patients in China, up to 7 days from symptom onset, showing statistically significant improvement in recovery with treatment, and non-statistically significant improvements in recovery time and deterioration.
Authors selectively omitted the p-value for recovery which shows statistical significance. Very little information on the patients is provided (only age, gender, and insurance status). The table, text, and abstract show three different versions of recovery numbers. The table and abstract show two different versions of recovery time. The abstract contains a hazard ratio that is not in the text, and no statistical methods are reported. Given the selective omission of the statistically significant recovery p-value, three different sets of numbers for that outcome, and other inconsistencies, the data in this study does not appear to be very reliable. Patients >50 were excluded.
Authors administered ivermectin on an empty stomach. Ivermectin is a lipophilic drug with low aqueous solubility and is better absorbed when given with food, especially high-fat meals. Administration with a high-fat meal can significantly increase plasma and tissue concentrations (~2.5x plasma concentration in Guzzo) and reduce time to onset of action. Standard practice for systemic use of ivermectin is administration with food (for intestinal parasitic infections, systemic distribution may not be required). Specifying fasted administration may avoid or delay the attainment of therapeutic concentrations and raises concerns about possible investigator bias.
This is the 32nd of 51 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000015.
This is the 75th of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
This study is excluded in the after exclusion results of meta analysis: very minimal patient information, three different results for the recovery outcome, selective omission of the statistically significant recovery p-value, and other inconsistencies.
risk of death, 4.0% higher, RR 1.04, p = 1.00, treatment 1 of 99 (1.0%), control 1 of 103 (1.0%).
deterioration of 2 or more points, 40.5% lower, RR 0.59, p = 0.54, treatment 4 of 99 (4.0%), control 7 of 103 (6.8%), NNT 36.
escalation of care, 14.9% lower, RR 0.85, p = 0.82, treatment 9 of 99 (9.1%), control 11 of 103 (10.7%), NNT 63.
fever during study, 17.9% lower, RR 0.82, p = 0.58, treatment 15 of 99 (15.2%), control 19 of 103 (18.4%), NNT 30.
risk of no recovery, 35.6% lower, RR 0.64, p = 0.04, treatment 26 of 99 (26.3%), control 42 of 103 (40.8%), NNT 6.9, primary outcome.
recovery time, 30.8% lower, relative time 0.69, p = 0.08, treatment 99, control 103, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Abbas et al., 31 Dec 2021, Double Blind Randomized Controlled Trial, placebo-controlled, China, peer-reviewed, 3 authors, study period May 2021 - August 2021, dosage 300μg/kg days 1-5. Contact:
This PaperIvermectinAll
The Effect of Ivermectin on Reducing Viral Symptoms in Patients with Mild COVID-19
K U Abbas, S Muhammad, S F Ding
Ivermectin is widely prescribed as a potential treatment for coronavirus disease 2019, despite uncertainty about its clinical benefit. To determine whether ivermectin is an efficacious treatment for mild coronavirus disease 2019 is the objective of the study. A total of 476 adult patients with mild symptoms for 7 d or fewer in Jinan, China, were enrolled and followed up. Patients were randomly selected to receive ivermectin, 300 μg/ kg body weight per day for 5 d or placebo. The median time to resolution of symptoms was 10 d (interquartile range, 9-13) in the ivermectin group whereas it was 12 d (interquartile range, 9-13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95 % confidence interval, 0.87 to 1.32]; p=0.53 by log-rank test). By d 21, 82 % in the ivermectin group and 79 % in the placebo group had resolved symptoms. The most common solicited adverse event was headache, reported by 104 patients (52 %) who received ivermectin and 111 patients (56 %) who received placebo. The most serious adverse event was multiorgan failure. Among adults with mild coronavirus disease 2019, a 5 d course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild coronavirus disease 2019.
Conflict of interests: The authors declared no conflict of interest.
Ansems, Grundeis, Dahms, Mikolajewska, Thieme et al., Remdesivir for the treatment of Covid-19, Cochrane Database Syst Rev
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of Covid-19, N Engl J Med
Bernal, Andrews, Gower, Gallagher, Simmons et al., Effectiveness of COVID-19 vaccines against the B. 1.617. 2 (Delta) variant, N Engl J Med
Bray, Rayner, Noël, Jans, Wagstaff, Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med
De Melo, Lazarini, Larrous, Feige, Kergoat et al., Anti-COVID-19 efficacy of ivermectin in the golden hamster, BioRxiv
Diazgranados-Sánchez, Mejía-Fernández, Ls, Valencia-Artunduaga, Costa, Ivermectina como coadyuvante en la epilepsia refractaria, Rev Neurol
Elgazzar, Hany, Youssef, Hafez, Moussa et al., efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic
Hashim, Maulood, Rasheed, Fatak, Kabah et al., Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Khan, Misdary, Yegya-Raman, Kim, Narayanan et al., Montelukast in hospitalized patients diagnosed with COVID-19, J Asthma
López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial, JAMA
Mastrangelo, Pezzullo, De Burghgraeve, Kaptein, Pastorino et al., Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: New prospects for an old drug, J Antimicrob Chemother
Momekov, Momekova, Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: Antiviral levels are not likely attainable with known dosing regimens, Biotechnol Biotechnol Equip
Niaee, Namdar, Allami, Zolghadr, Javadi et al., Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multicenter clinical trial, Asian Pac J Trop Biomed
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ivermectin in COVID nineteen study, Chest
Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther
Smit, Ochomo, Aljayyoussi, Kwambai, Abong et al., Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisininpiperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): A randomised, double-blind, placebo-controlled trial, Lancet Infect Dis
Spuch, López-García, Rivera-Baltanás, Rodrígues-Amorím, Olivares, Does lithium deserve a place in the treatment against COVID-19? A preliminary observational study in six patients, case report, Front Pharmacol
Tay, Fraser, Chan, Moreland, Rathore et al., Nuclear localization of dengue virus (DENV) 1-4 nonstructural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antiviral Res
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Wang, Wang, Chen, Qin, Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures, J Med Virol
Xu, Shi, Wang, Zhang, Huang et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med
Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Res
{ 'indexed': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T16:36:44Z', 'timestamp': 1711643804015}, 'reference-count': 0, 'publisher': 'Indian Pharmaceutical Association - IPA', 'issue': 'S1', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.36468/pharmaceutical-sciences.spl.416', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 18]], 'date-time': '2022-03-18T12:23:08Z', 'timestamp': 1647606188000}, 'source': 'Crossref', 'is-referenced-by-count': 2, 'title': 'The Effect of Ivermectin on Reducing Viral Symptoms in Patients with Mild COVID-19', 'prefix': '10.36468', 'volume': '84', 'author': [ {'given': 'K. U.', 'family': 'Abbas', 'sequence': 'first', 'affiliation': []}, {'given': 'S.', 'family': 'Muhammad', 'sequence': 'additional', 'affiliation': []}, {'given': 'S. F.', 'family': 'Ding', 'sequence': 'additional', 'affiliation': []}], 'member': '22282', 'published-online': {'date-parts': [[2022]]}, 'container-title': 'Indian Journal of Pharmaceutical Sciences', 'original-title': [], 'deposited': { 'date-parts': [[2022, 3, 18]], 'date-time': '2022-03-18T12:23:10Z', 'timestamp': 1647606190000}, 'score': 1, 'resource': { 'primary': { 'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022]]}, 'references-count': 0, 'journal-issue': {'issue': 'S1', 'published-online': {'date-parts': [[2022]]}}, 'URL': '', 'relation': {}, 'container-title-short': 'IJPS', 'published': {'date-parts': [[2022]]}}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop